Medication info
Posidapam Extended-Release Tablets 5/500 mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)

Posidapam Extended-Release Tablets 5/500 mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletDapagliflozin Propanediol Hydrate›6.15mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Orange rectangular extended-release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP) x 5]
Approval status
Active

MFDS item code 202302566 · Approved 2023.08.30 · Insurance code 694004080

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally taken once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's previous metformin dose or an appropriately close therapeutically equivalent dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, this medicine may be started at the previous doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used concomitantly with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering medicines. Since any change may cause alterations in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary for patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who have no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. Discontinue this medicine immediately if the eGFR falls below 45 mL/min/1.73m2. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted by the kidneys, and elderly patients are more likely to have decreased renal function; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Use in Elderly Patients).

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication helps adult patients with Type 2 diabetes control their blood sugar levels when used with dapagliflozin and metformin. It is particularly used as an adjunct to a treatment regimen that includes diet and exercise. For patients with Type 2 diabetes whose blood sugar is not adequately controlled and who have cardiovascular disease or risk factors, it is necessary to consult with a specialist regarding the impact of dapagliflozin on cardiovascular events. This medication plays a crucial role in improving blood sugar control and can be safely used according to the patient's condition.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally taken once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's previous metformin dose or an appropriately close therapeutically equivalent dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, this medicine may be started at the previous doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used concomitantly with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering medicines. Since any change may cause alterations in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary for patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who have no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. Discontinue this medicine immediately if the eGFR falls below 45 mL/min/1.73m2. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted by the kidneys, and elderly patients are more likely to have decreased renal function; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Use in Elderly Patients).

Precautions

This medication is used to treat diabetes and contains two main active ingredients. Firstly, metformin hydrochloride, one of the components, helps lower blood sugar, but can rarely cause a serious side effect known as lactic acidosis. Lactic acidosis is a dangerous condition that occurs when there is an abnormal accumulation of lactic acid in the body and can present symptoms like difficulty breathing, muscle pain, fatigue, and abdominal pain. Secondly, dapagliflozin, the other component, helps control blood sugar by promoting the excretion of sugar from the kidneys into the urine. However, it can cause fluid volume depletion and low blood pressure, so caution is advised, particularly for patients with impaired kidney function, older adults, or those on diuretics. This medication should not be administered to patients with severe kidney impairment, dehydration, severe infections, unstable heart function, Type 1 diabetes, pregnant or breastfeeding women, etc. Additionally, using this medication in conjunction with insulin or sulfonylureas can increase the risk of hypoglycemia, so dosage adjustments are necessary when using these medications together. This medication can increase the risk of genital infections and urinary tract infections, so if related symptoms occur, patients should consult healthcare professionals immediately. Regular monitoring of kidney function and fluid status is required during treatment, and any abnormal symptoms should be promptly reported to a physician. Women who are pregnant or may become pregnant should not take this medication, and breastfeeding women should also avoid it. Finally, the risk of lactic acidosis may increase when taken with alcohol, so excessive drinking should be avoided during treatment. This medication has not established safety and efficacy in children, so it should not be used in pediatric patients. It is important to follow the prescribed dosage and instructions from a doctor and to receive regular check-ups while being vigilant for adverse reactions.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • painful urination
  • polyuria
  • nocturia
  • itching of the vulva
  • itching of the genitals
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignancy
  • uterine fibroid
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • joint pain
  • muscle pain
  • myofascial pain syndrome
  • osteoarthritis
  • chondromalacia
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering and should be kept at room temperature between 1 and 30 degrees Celsius. By doing so, the medication's efficacy can be safely maintained.

Appearance and packaging

Appearance

Orange rectangular extended-release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP) x 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.